BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26681532)

  • 1. Normal hematopoiesis and lack of β-catenin activation in osteoblasts of patients and mice harboring Lrp5 gain-of-function mutations.
    Galán-Díez M; Isa A; Ponzetti M; Nielsen MF; Kassem M; Kousteni S
    Biochim Biophys Acta; 2016 Mar; 1863(3):490-498. PubMed ID: 26681532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
    Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
    Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation.
    Haÿ E; Laplantine E; Geoffroy V; Frain M; Kohler T; Müller R; Marie PJ
    Mol Cell Biol; 2009 Feb; 29(4):953-64. PubMed ID: 19075000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
    Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
    J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism.
    Kang KS; Hong JM; Horan DJ; Lim KE; Bullock WA; Bruzzaniti A; Hann S; Warman ML; Robling AG
    Bone; 2019 Mar; 120():166-175. PubMed ID: 30409757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-375-3p negatively regulates osteogenesis by targeting and decreasing the expression levels of LRP5 and β-catenin.
    Sun T; Li CT; Xiong L; Ning Z; Leung F; Peng S; Lu WW
    PLoS One; 2017; 12(2):e0171281. PubMed ID: 28158288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
    Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
    J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5.
    Lee GS; Simpson C; Sun BH; Yao C; Foer D; Sullivan B; Matthes S; Alenina N; Belsky J; Bader M; Insogna KL
    J Bone Miner Res; 2014 Apr; 29(4):976-81. PubMed ID: 24038240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: applications in mice with bone property altering Lrp5 mutations.
    Ayturk UM; Jacobsen CM; Christodoulou DC; Gorham J; Seidman JG; Seidman CE; Robling AG; Warman ML
    J Bone Miner Res; 2013 Oct; 28(10):2081-93. PubMed ID: 23553928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-based mediated disruption of N-cadherin-LRP5/6 interaction promotes Wnt signaling and bone formation.
    Haÿ E; Buczkowski T; Marty C; Da Nascimento S; Sonnet P; Marie PJ
    J Bone Miner Res; 2012 Sep; 27(9):1852-63. PubMed ID: 22576936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain-of-Function Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes.
    Leanza G; Fontana F; Lee SY; Remedi MS; Schott C; Ferron M; Hamilton-Hall M; Alippe Y; Strollo R; Napoli N; Civitelli R
    J Bone Miner Res; 2021 Jul; 36(7):1403-1415. PubMed ID: 33831261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
    Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
    J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
    Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
    J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.
    Bhat BM; Allen KM; Liu W; Graham J; Morales A; Anisowicz A; Lam HS; McCauley C; Coleburn V; Cain M; Fortier E; Bhat RA; Bex FJ; Yaworsky PJ
    Gene; 2007 Apr; 391(1-2):103-12. PubMed ID: 17276019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA LINC00707 promotes osteogenic differentiation of hBMSCs through the Wnt/β-catenin pathway activated by LINC00707/miR-145/LRP5 axis.
    Cai WL; Zeng W; Liu HH; Zhu BY; Liu JL; Liu Y
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):18-28. PubMed ID: 31957814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition.
    Riddle RC; Diegel CR; Leslie JM; Van Koevering KK; Faugere MC; Clemens TL; Williams BO
    PLoS One; 2013; 8(5):e63323. PubMed ID: 23675479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrantly activated Wnt/β-catenin pathway co-receptors LRP5 and LRP6 regulate osteoblast differentiation in the developing coronal sutures of an Apert syndrome (Fgfr2
    Min Swe NM; Kobayashi Y; Kamimoto H; Moriyama K
    Dev Dyn; 2021 Mar; 250(3):465-476. PubMed ID: 32822074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterozygous deletion of LRP5 gene in mice alters profile of immune cells and modulates differentiation of osteoblasts.
    Li L; Wang Y; Zhang N; Zhang Y; Lin J; Qiu X; Gui Y; Wang F; Li D; Wang L
    Biosci Trends; 2018 Jul; 12(3):266-274. PubMed ID: 29899194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Missense Mutations in LRP5 Associated with High Bone Mass Protect the Mouse Skeleton from Disuse- and Ovariectomy-Induced Osteopenia.
    Niziolek PJ; Bullock W; Warman ML; Robling AG
    PLoS One; 2015; 10(11):e0140775. PubMed ID: 26554834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
    Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
    J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.